ProPhase Labs Inc (PRPH)
2.46
+0.06
(+2.50%)
USD |
NASDAQ |
Oct 04, 16:00
2.47
+0.01
(+0.41%)
After-Hours: 20:00
ProPhase Labs Research and Development Expense (Annual): 1.418M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.418M |
| December 31, 2022 | 0.652M |
| December 31, 2021 | 0.52M |
| December 31, 2020 | 0.633M |
| December 31, 2019 | 0.332M |
| December 31, 2018 | 0.398M |
| December 31, 2017 | 0.431M |
| December 31, 2016 | 0.358M |
| December 31, 2015 | 0.34M |
| December 31, 2014 | 1.322M |
| December 31, 2013 | 0.824M |
| December 31, 2012 | 1.301M |
| Date | Value |
|---|---|
| December 31, 2011 | 1.088M |
| December 31, 2010 | 0.794M |
| December 31, 2009 | 1.308M |
| December 31, 2008 | 4.241M |
| December 31, 2007 | 6.482M |
| December 31, 2006 | 3.788M |
| December 31, 2005 | 3.784M |
| December 31, 2004 | 3.233M |
| December 31, 2003 | 3.366M |
| December 31, 2002 | 2.663M |
| December 31, 2001 | 1.332M |
| December 31, 2000 | 1.186M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
0.332M
Minimum
2019
1.418M
Maximum
2023
0.711M
Average
0.633M
Median
2020
Research and Development Expense (Annual) Benchmarks
| Fonar Corp | 1.736M |
| XWELL Inc | -- |
| Applied DNA Sciences Inc | 3.735M |
| Veracyte Inc | 57.30M |
| OncoCyte Corp | 9.294M |